

Amendments to the Specification:

On page 14 of the specification as filed, please amend Table 1 as follows:

Table 1. NF-kappa-B target and siRNA compound sequences (5'-3')

Target Sequence		
SEQ ID NO	Sequence	Applicant's reference no.
1	AAGGACCUAUGAGACCUUCAA	IDX 101
2	AAGAUCAAUGGCUACACAGGA	IDX 105
3	AACACUGCCGAGCUCAAGAUC	IDX 106
4	GAGUCAGAUCAGCUCCUAAGG	IDX 107
Lower Sequence		
SEQ ID NO	Sequence	Applicant's reference no.
5	UUGAAGGUCUCAUAGGUCC(D)TT *	IDX 121
6	UCCUGUGUAGCCAUUGAUC(D)TT	IDX 125
7	GAUCUUGAGCUCGGCAGUG(D)TT	IDX 126
8	CCUUAGGAGCUGAUCUGAC(D)TT	IDX 127
Upper Sequence		
SEQ ID NO	Sequence	Applicant's reference no.
9	GGACCUAUGAGACCUUCAA(D)TT*	IDX 131
10	GAUCAAUGGCUACACAGGA(D)TT	IDX 135
11	CACUGCCGAGCUCAAGAUC(D)TT	IDX 136
12	GUCAGAUCAGCUCCUGGAA(D)TT GUCAGAUCAGCUCCUAAGG(D)TT	IDX 137

Notes:

* denotes that siRNA compound composed of antisense ~~stand~~ strand SEQ ID NO 5 annealed with sense strand SEQ ID NO 9 that was used in the animal proof of concept studies.

Compounds synthesized as RNA oligonucleotides with the last two nucleotides from the 3' end are DNA, denoted as (D).